Pathogenesis of skeletal muscle insulin resistance in type 2 diabetes mellitus

American Journal of Cardiology

Volumn 90, Issue 5 SUPPL., 2002, Pages 11-18

  Petersen, Kitt F ^a   Shulman, Gerald I ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; FAT; FATTY ACID; GLUCOSE; GLUCOSE TRANSPORTER 4; GLYCOGEN; GLYCOGEN SYNTHASE; HEXOKINASE; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN SERINE KINASE; THIAZOLIDINE DERIVATIVE; TROGLITAZONE;

ADIPOCYTE; CELL METABOLISM; CLINICAL FEATURE; DISEASE COURSE; ENZYME ACTIVATION; ENZYME ACTIVITY; FATTY ACID METABOLISM; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCOGEN SYNTHESIS; HUMAN; HYPOTHESIS; INSULIN RESISTANCE; INSULIN RESPONSE; LIVER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SKELETAL MUSCLE;

EID: 0037026745     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(02)02554-7     Document Type: Article

References (35)

1. Powers A.C. Diabetes mellitus. Braunwald E., Fauci A.S., Kasper D.L., Hauser S.L., Longo D.L., Jameson J.L., Harrison's Principles of Internal Medicine. 15th Ed. 2001;2109-2137 McGraw-Hill, New York.
2. Morris F., White C., Kahn R. Molecular aspects of insulin action. Kahn C.R., Weir G.C., Joslin's Diabetes Mellitus. 13th Ed:1994;139-162 Lippincott Williams & Wilkins, Philadelphia.
3. Warram J.H., Martin B.C., Krolewski A.S., Soeldner J.S., Kahn C.R. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med. 113:1990;909-915.
4. DeFronzo R.A., Bonadonna R.C., Ferrannini E. Pathogenesis of NIDDM a balanced overview . Diabetes Care. 15:1992;318-368.
5. 13C nuclear magnetic resonance spectroscopy. N Engl J Med. 322:1990;223-228.
6. Cline G.W., Falk Petersen K., Krssak M., Shen J., Hundal R.S., Trajanoski Z., Inzucchi S., Dresner A., Rothman D.L., Shulman G.I. Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes. N Engl J Med. 341:1999;240-246.
7. 31P nuclear magnetic resonance measurements of muscle glucose-6-phosphate evidence for reduced insulin-dependent muscle glucose transport or phosphorylation activity in non-insulin-dependent diabetes mellitus . J Clin Invest. 89:1992;1069-1075.
8. Eriksson J., Franssila-Kallunki A., Ekstrand A., Saloranta C., Widen E., Schalin C., Groop L. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med. 321:1989;337-343.
9. Lillioja S., Mott D.M., Howard B.V., Bennett P.H., Yki-Jarvinen H., Freymond D., Nyomba B.L., Zurlo F., Swinburn B., Bogardus C. Impaired glucose tolerance as a disorder of insulin action longitudinal and cross-sectional studies in Pima Indians . N Engl J Med. 318:1988;1217-1225.
10. Rothman D.L., Magnusson I., Cline G., Gerard D., Kahn C.R., Shulman R.G., Shulman G.I. Decreased muscle glucose transport/phosphorylation is an early defect in the pathogenesis of non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci USA. 92:1995;983-987.
11. Perseghin G., Ghosh S., Gerow K., Shulman G.I. Metabolic defects in lean nondiabetic offspring of NIDDM parents a cross-sectional study . Diabetes. 46:1997;1001-1009.
12. 1H NMR spectroscopy study. Diabetologia. 1999;113-116. [published correction appears in Diabetologia 1999;42:1-2].
13. 13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents . Diabetes. 48:1999;1600-1606.
14. Randle P.J., Garland P.B., Hales C.N., Newsholme E.A. The glucose fatty-acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. i:1963;785-789.
15. Roden M., Price T.B., Perseghin G., Petersen K.F., Rothman D.L., Cline G.W., Shulman G.I. Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest. 97:1996;2859-2865.
16. Dresner A., Laurent D., Marcucci M., Griffin M.E., Dufour S., Cline G.W., Slezak L.A., Andersen D.K., Hundal R.S., Rothman D.L., Petersen K.F., Shulman G.I. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest. 103:1999;253-259.
17. Shulman G.I. Cellular mechanisms of insulin resistance. J Clin Invest. 106:2000;171-176.
18. Griffin M.E., Marcucci M.J., Cline G.W., Bell K., Barucci N., Lee D., Goodyear L.J., Kraegen E.W., White M.F., Shulman G.I. Free fatty acid-induced insulin resistance is associated with activation of protein kinase C θ and alterations in the insulin signaling cascade. Diabetes. 48:1999;1270-1274.
19. Yu C., Chen Y., Zong H., Wang Y., Bergerson R., Kim J.K., Cline G.W., Cushman S.W., Cooney G.J., Atcheson B., White M.F., Kraegen E.W., Shulman G.I. Mechanism by which fatty acids inhibit insulin activation of IRS-1 associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem. 2002;. (in press).
20. Moitra J., Mason M.M., Olive M., Krylov D., Gavrilova O., Marcus-Samuels B., Feigenbaum L., Lee E., Aoyama T., Eckhaus M., Reitman M.L., Vinson C. Life without white fat a transgenic mouse . Genes Dev. 12:1998;3168-3181.
21. Kim J.K., Gavrilova O., Chen Y., Reitman M.L., Shulman G.I. Mechanism of insulin resistance in A-ZIP/F-1 fatless mice. J Biol Chem. 275:2000;8456-8460.
22. Hotamisligil G.S. The role of TNF alpha and TNF receptors in obesity and insulin resistance. J Intern Med. 245:1999;621-625.
23. Mohamed-Ali V., Pinkney J.H., Coppack S.W. Adipose tissue as an endocrine and paracrine organ. Int J Obes Relat Metab Disord. 22:1998;1145-1158.
24. Shimomura I., Hammer R.E., Ikemoto S., Brown M.S., Goldstein J.L. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature. 401:1999;73-76.
25. Steppan C.M., Bailey S.T., Bhat S., Brown E.J., Banerjee R.R., Wright C.M., Patel H.R., Ahima R.S., Lazar M.A. The hormone resistin links obesity to diabetes. Nature. 409:2001;307-312.
26. Kim J.K., Fillmore J.J., Chen Y., Yu C., Moore I.K., Pypaert M., Lutz E.P., Kako Y., Velez-Carrasco W., Goldberg I.J., Breslow J.L., Shulman G.I. Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc Natl Acad Sci USA. 98:2001;7522-7527.
27. Saltiel A.R., Olefsky J.M. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 45:1996;1661-1669.
28. Yu J.G., Kruszynska Y.T., Mulford M.I., Olefsky J.M. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients. Diabetes. 48:1999;2414-2421.
29. Maggs D.G., Buchanan T.A., Burant C.F., Cline G., Gumbiner B., Hsueh W.A., Inzucchi S., Kelly D., Nolan J., Olefsky J.M., Polonsky K.S., Silver D., Valiquett T.R., Shulman G.I. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus a randomized, double-blind, placebo-controlled trial . Ann Intern Med. 128:1998;176-185.
30. Inzucchi S.E., Maggs D.G., Spollett G.R., Page S.L., Rife F.S., Walton V., Shulman G.I. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med. 338:1998;867-872.
31. Saltiel A.R., Olefsky J.M. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 45:1996;1661-1669.
32. Petersen K.F., Krssak M., Inzucchi S., Cline G.W., Dufour S., Shulman G.I. Mechanism of troglitazone action in type 2 diabetes. Diabetes. 49:2000;827-831.
33. Mayerson A.B., Hundal R., Dufour S., Lebon V., Befroy D., Cline G.W., Enocksson S., Inzucchi S.E., Shulman G.I., Petersen K.F. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes. 51:2002;797-802.
34. Hundal R.S., Krssak M., Dufour S., Laurent D., Lebon V., Chandramouli V., Inzucchi S.E., Schumann W.C., Petersen K.F., Landau B.R., Shulman G.I. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes. 49:2000;2063-2069.
35. Peterson KF, Oral EA, Dufour S, Befroy D, Ariyan C, Yu C, Cline GW, DePaoli AM, Taylor SI, Gordon P, Shulman GJ. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest 2002;109:1345-1350.